Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BeiGene, Ltd. is a biotechnology company focused on developing innovative medicines for cancer treatment, with a strong presence in China and expanding operations in the U.S. Its proprietary drug pipeline includes targeted therapies and immunotherapies, particularly in hematologic malignancies and solid tumors, which drives its stock performance.
BeiGene generates revenue primarily through the sale of its oncology products, including BRUKINSA and Tislelizumab. The company's competitive advantages include a robust R&D pipeline, strategic partnerships with global pharmaceutical companies, and a strong foothold in the Chinese market, which is the second-largest pharmaceutical market globally.
FDA approvals for new oncology drugs
Partnership announcements with major pharmaceutical companies
Clinical trial results for pipeline candidates
Market penetration in China and the U.S.
Regulatory changes affecting drug approvals and pricing
Technological disruption in drug development processes
Intense competition from other biotech firms and large pharmaceutical companies
Potential for generic competition as patents expire
Moderate liquidity risk given the current ratio of 3.64, though manageable
Potential risks associated with future capital raises if needed
moderate - as a biotech firm, BeiGene's performance is somewhat insulated from economic cycles, but healthcare spending is influenced by GDP growth and consumer spending.
Rising interest rates could increase the company's financing costs for R&D and operational expenses, potentially impacting valuation multiples.
minimal - the company has a manageable debt-to-equity ratio of 0.43, indicating low reliance on external financing.
growth - investors are likely attracted to the high revenue growth potential and innovative drug pipeline.
high - the stock has shown significant price fluctuations, evidenced by a 3-month return of -10.3%.
